Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation.
Fuchun YangShaogang SunChenran WangMichael HaasSyn YeoJun-Lin GuanPublished in: British journal of cancer (2020)
These studies suggest a potential new treatment strategy for mTORC1-driven cancers like lymphangiosarcoma through an alternative mechanism.